Clinical Trial Update: 3-AP and Gemcitabine in Treating Patients With Unresectable or Metastatic Pancreatic Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluated Triapine (3-AP) in combination with gemcitabine for unresectable or metastatic pancreatic cancer; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• Gemcitabine (Gemcitabine)
• Triapine (Triapine)

Snippet

Sponsor: Vion Pharmaceuticals | Conditions: Pancreatic Cancer | Phase 2 | Status: COMPLETED